HDAC inhibitors induce cell cycle arrest, activate the apoptotic extrinsic pathway and synergize with a novel PIM inhibitor in Hodgkin lymphoma-derived cell lines

British Journal of Haematology

Volumn 152, Issue 3, 2011, Pages 352-356

  Martín Sánchez, Esperanza ^a,b   Sánchez Beato, Margarita ^a   Rodríguez, María Elena ^a   Sánchez Espiridión, Beatriz ^a   Gómez Abad, Cristina ^a   Bischoff, James R ^a   Piris, Miguel A ^a   García Orad, África ^b   García, Juan F ^a,c  

^a Structural Biology and Biocomputing Programme   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

Author keywords

Extrinsic apoptosis; Gene expression; HDAC inhibitors; Hodgkin lymphoma; PIM inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BUTYRIC ACID; DEATH RECEPTOR; HISTONE DEACETYLASE INHIBITOR; PIM INHIBITOR; PROTEIN BCL 2; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION REGULATION; HODGKIN DISEASE; HUMAN; LETTER; LYMPHOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; PROTO ONCOGENE PIM1; PROTO ONCOGENE PIM2; UPREGULATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HODGKIN DISEASE; HUMANS; PROTO-ONCOGENE PROTEINS C-PIM-1; TUMOR CELLS, CULTURED;

EID: 78651335925     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08401.x     Document Type: Letter

References (10)

1. Bhalla, S., Balasubramanian, S., David, K., Sirisawad, M., Buggy, J., Mauro, L., Prachand, S., Miller, R., Gordon, L.I. & Evens, A.M. (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clinical Cancer Research, 15, 3354-3365.
2. Buglio, D., Georgakis, G.V., Hanabuchi, S., Arima, K., Khaskhely, N.M., Liu, Y.J. & Younes, A. (2008) Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood, 112, 1424-1433.
3. Feuerborn, A., Moritz, C., Von Bonin, F., Dobbelstein, M., Trumper, L., Sturzenhofecker, B. & Kube, D. (2006) Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leukemia and Lymphoma, 47, 1932-1940.
4. Garcia, J.F., Camacho, F.I., Morente, M., Fraga, M., Montalban, C., Alvaro, T., Bellas, C., Castano, A., Diez, A., Flores, T., Martin, C., Martinez, M.A., Mazorra, F., Menarguez, J., Mestre, M.J., Mollejo, M., Saez, A.I., Sanchez, L. & Piris, M.A. (2003) Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood, 101, 681-689.
5. Gillenwater, A.M., Zhong, M. & Lotan, R. (2007) Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Molecular Cancer Therapeutics, 6, 2967-2975.
6. Gloghini, A., Buglio, D., Khaskhely, N.M., Georgakis, G., Orlowski, R.Z., Neelapu, S.S., Carbone, A. & Younes, A. (2009) Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors. British Journal of Haematology, 147, 515-525.
7. Hartlapp, I., Pallasch, C., Weibert, G., Kemkers, A., Hummel, M. & Re, D. (2009) Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leukemia Research, 33, 929-936.
8. Küppers, R. (2009) The biology of Hodgkin's lymphoma. Nature Reviews Cancer, 9, 15-27.
9. Mathas, S., Lietz, A., Anagnostopoulos, I., Hummel, F., Wiesner, B., Janz, M., Jundt, F., Hirsch, B., Johrens-Leder, K., Vornlocher, H.P., Bommert, K., Stein, H. & Dorken, B. (2004) c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. The Journal of Experimental Medicine, 199, 1041-1052.
10. Sanchez-Aguilera, A., Montalban, C., de la Cueva, P., Sanchez-Verde, L., Morente, M.M., Garcia-Cosio, M., Garcia-Larana, J., Bellas, C., Provencio, M., Romagosa, V., de Sevilla, A.F., Menarguez, J., Sabin, P., Mestre, M.J., Mendez, M., Fresno, M.F., Nicolas, C., Piris, M.A. & Garcia, J.F. (2006) Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood, 108, 662-668.